Skip to main
TRAW

Traws Pharma (TRAW) Stock Forecast & Price Target

Traws Pharma (TRAW) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Traws Pharma is well positioned to capitalize on the increasing demand for antiviral drugs with its promising pipeline and strategic collaborations. With a strong focus on both respiratory diseases and cancer, the company has potential for significant revenue growth and value creation in the near future. Its inclusion in the U.S. Strategic National Stockpile could serve as a major catalyst for its success.

Bears say

Traws Pharma is making progress in their clinical programs, but their reliance on external organizations and potential competition in the antiviral market poses risks. While TXM and Ratutrelvir show potential, a high-risk commercialization process and delays could hinder the company's success in the competitive pharmaceutical industry. It is important for investors to carefully monitor the company's progress and commercialization efforts before making any investment decisions.

Traws Pharma (TRAW) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Traws Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Traws Pharma (TRAW) Forecast

Analysts have given Traws Pharma (TRAW) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Traws Pharma (TRAW) has a Strong Buy consensus rating as of Jun 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Traws Pharma (TRAW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.